Summary
IRIS International, Inc. (Iris) designs, develops, manufactures and markets in-vitro diagnostic systems that analyze particles and living cell forms and structures of a variety of body fluids. The company carries out its business through three divisions, namely, Iris Diagnostics, Iris Sample Processing and Iris Personalized Medicine. Its major products include in-vitro diagnostic urinalysis systems, integrated urinalysis software, sample collection systems, sample processing systems, benchtop centrifuges, small instruments and supplies. It also develops and commercialize NADiA ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious diseases. The company exports its products to more than 50 countries. Iris is a subsidiary of Danaher Corporation and is headquartered in California, the US.
The company seeks to maintain a leading position in automated in vitro diagnostics for urinalysis and sample processing at the same time becoming a global leader in hematology and molecular diagnostics by offering efficient products and solutions.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company IRIS International, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
IRIS International, Inc. Company Snapshot 4
IRIS International, Inc. Company Overview 4
Key Information 4
IRIS International, Inc. Pipeline Products and Clinical Trials Overview 5
IRIS International, Inc. – Pipeline Analysis Overview 7
Business Description 7
Key Facts 7
IRIS International, Inc. - Major Products and Services 9
IRIS International, Inc. Pipeline Products by Development Stage 10
IRIS International, Inc. Pipeline Products Overview 12
3GEMS Hematology Analyzer 12
3GEMS Hematology Analyzer Product Overview 12
3GEMS Next Generation Urinalysis Platform 13
3GEMS Next Generation Urinalysis Platform Product Overview 13
NADIA CEC - Breast Cancer 14
NADIA CEC - Breast Cancer Product Overview 14
NADIA CEC - Prostate Cancer 15
NADIA CEC - Prostate Cancer Product Overview 15
NADiA HIV 16
NADiA HIV Product Overview 16
IRIS International, Inc. - Key Competitors 17
IRIS International, Inc. - Key Employees 18
IRIS International, Inc. - Key Employee Biographies 19
IRIS International, Inc. - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 22
IRIS International, Inc., Recent Developments 22
Sep 20, 2012: Iris International To Present NADiA ProsVue At Two Meetings In Washington DC 22
Aug 16, 2012: IRIS International Selects ThingWorx For Next-Generation Remote Service And Support Of Medical Devices 22
Jul 31, 2012: IRIS International Reports Revenue Of $30.9m In Q2 2012 23
Jun 06, 2012: IRIS International Announces Clinical Data Presentation Of NADiA ProsVue Benefits At 5th International Symposium On Focal Therapy And Imaging In Prostate And Kidney Cancer 24
May 21, 2012: Iris International Unveils NADiA ProsVue At AUA Annual Meeting 25
May 02, 2012: IRIS International Reports Revenue Of $29.9m In Q1 2012 25
Mar 19, 2012: IRIS International Commences Commercial Shipment Of ThermoBrite Elite 26
Mar 01, 2012: IRIS International Reports Revenue Of $118.3m In 2011 27
Feb 21, 2012: IRIS Launches NADiA ProsVue Prognostic Cancer Test In US 28
Nov 17, 2011: IRIS Introduces ThermoBrite Elite AMP 2011 Annual Meeting 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List Of Tables
List of Tables
IRIS International, Inc., Key Facts 4
IRIS International, Inc. Pipeline Products and Clinical Trials Overview 5
IRIS International, Inc. Pipeline Products by Equipment Type 5
IRIS International, Inc. Pipeline Products by Indication 6
IRIS International, Inc., Key Facts 8
IRIS International, Inc., Major Products and Services 9
IRIS International, Inc. Number of Pipeline Products by Development Stage 10
IRIS International, Inc. Pipeline Products Summary by Development Stage 11
3GEMS Hematology Analyzer - Product Status 12
3GEMS Hematology Analyzer - Product Description 12
3GEMS Next Generation Urinalysis Platform - Product Status 13
3GEMS Next Generation Urinalysis Platform - Product Description 13
NADIA CEC - Breast Cancer - Product Status 14
NADIA CEC - Breast Cancer - Product Description 14
NADIA CEC - Prostate Cancer - Product Status 15
NADIA CEC - Prostate Cancer - Product Description 15
NADiA HIV - Product Status 16
NADiA HIV - Product Description 16
IRIS International, Inc., Key Employees 18
IRIS International, Inc., Key Employee Biographies 19
IRIS International, Inc., Other Locations 20
IRIS International, Inc., Subsidiaries 20
List Of Figures
List of Figures
IRIS International, Inc. Pipeline Products by Equipment Type 5
IRIS International, Inc. Pipeline Products by Development Stage 10
